Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
H. Nüßlein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Manuela Le Bars(Bristol-Myers Squibb (France)), C. Rauch(Link Foundation), M. Chartier, Rieke Alten(Schlosspark-Klinik), Michael T. Nurmohamed(Reade), Gerd R Burmester(Charité - Universitätsmedizin Berlin), P. Peichl(Evangelisches Krankenhaus Düsseldorf), Karel Pavelká(Institute of Rheumatology), Mauro Galeazzi(University of Siena), Hans Peter(University Medical Center Freiburg), Hanns M. Lorenz(Friedrich-Alexander-Universität Erlangen-Nürnberg), W. Bensen(St. Joseph Hospital), Coralie Poncet(European Organisation for Research and Treatment of Cancer)
PubMed
August 5, 2016
Cited by 32
Related Papers
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency
|Nature Immunology|2003|730